TABLE 1.
Demographic characteristics of participants at baseline and the two-year follow-up visits.
| Baseline (n=399) |
Follow-Up (n=312) |
|
|---|---|---|
| Male sex [n (%)] | 211 (53%) | 158 (51%) |
| Age (years) [mean (SD)] | 35 (8) | 37 (8) |
| Education (years) [mean (SD)] | 5 (3) | 6 (3) |
| Body Mass Index [mean (SD)] | 21.8 (3.5) | 22.8 (3.5) |
| Underweight [n (%)] | 51 (13%) | 16 (5%) |
| Normal [n (%)] | 295 (74%) | 234 (75%) |
| Overweight/Obese [n (%)] | 53 (13%) | 62 (20%) |
| CD4 count [median (IQR)] | --- | 394 [278, 530] |
| CD4 < 200 cells/μL [n (%)] | 200 (50%) | --- |
| CD4 350–500 cells/μL [n (%)] | 199 (50%) | --- |
| Plasma HIV viral load [median (IQR)] | 52510 [9050, 164,064] |
0 [0, 0] |
| HAND Category [n (%)] | ||
| Normal | 164 (41%) | 150 (48%) |
| ANI | 24 (6%) | 42 (13%) |
| MND | 151 (38%) | 105 (34%) |
| HAD | 60 (15%) | 15 (5%) |
| 25-OH vitamin D (ng/mL) [mean (SD)] | 36 (10) | --- |
| Low (≤ 20 ng/mL) [n (%)] | 16 (4%) | --- |
| Sufficient (21–40 ng/mL) [n (%)] | 251 (63%) | --- |
| Optimal (>40 ng/mL) [n (%)] | 132 (33%) | --- |
| Serum VDBP (ng/mL) [mean (SD)] | 316 (61) | --- |
| CSF VDBP (ng/mL) [mean (SD)] | 238 (33) | --- |
Abbreviations: 25-OH vitamin D: 25-hydroxyvitamin D; ANI: asymptomatic neurocognitive disorder; CSF: cerebrospinal fluid; HAD: HIV-associated dementia; HAND: HIV-associated neurocognitive disorder; HIV: human immunodeficiency virus; MND: minor neurocognitive disorder; SD: standard deviation; VDBP: vitamin D binding protein